Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

1.7%

1 terminated/withdrawn out of 60 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

36 recruiting

Enrollment Performance

Analytics

Phase 1
56(94.9%)
Early Phase 1
2(3.4%)
Phase 2
1(1.7%)
59Total
Phase 1(56)
Early Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials
NCT07715630Phase 1Recruiting

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

Role: lead

NCT05396300Phase 1Completed

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Role: collaborator

NCT07696481Early Phase 1Not Yet Recruiting

Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia

Role: collaborator

NCT05538195Phase 1Completed

Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors

Role: lead

NCT04348643Phase 1Withdrawn

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

Role: lead

NCT05415475Phase 1Completed

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Role: lead

NCT07637929Not Yet Recruiting

Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Role: lead

NCT07456371Phase 1Recruiting

PIC1 Injection Therapy for Relapsed/Refractory B-NHL

Role: lead

NCT07403097Phase 1Recruiting

Study of CD19 CAR-T Therapy for Refractory SLE

Role: lead

NCT06222853Phase 1Active Not Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

Role: collaborator

NCT07318259Phase 1Recruiting

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Role: lead

NCT06821048Phase 1Recruiting

Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors

Role: collaborator

NCT07331467Phase 1Recruiting

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Role: lead

NCT06892145Phase 1Recruiting

Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE

Role: lead

NCT07250386Phase 1Recruiting

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

Role: collaborator

NCT07247396Phase 1Recruiting

CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases

Role: collaborator

NCT07239323Phase 1Recruiting

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Role: lead

NCT07179692Phase 1Recruiting

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

Role: lead

NCT07181720Phase 1Recruiting

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Role: lead

NCT07184450Phase 1Recruiting

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Role: lead